Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
Price : $35 *
At a glance
- Drugs Losmapimod (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Jun 2016 Status changed from active, no longer recruiting to completed.
- 10 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016, according to ClinicalTrials.gov record.
- 10 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.